

CLSA Emerging Markets Healthcare Forum


1st December 2010

Mark Reilly General Manager, China Pharma and HK

Establishing a comprehensive presence in China



China – A significant GSK market with both Rx and Consumer presence



CER growth; China includes HK for charts RoW Consumer is all markets excluding US and Europe

Healthcare reform impacts

Today


- Branded generics
- Originator product price premium
- Weak IP protection
- Central government control
- Local manufacturing important
- Clinical development important
- Complex drug approval process

Future ~2020

- R&D driven market, premium price for innovation
- Harmonisation of generic prices
- Stronger IP protection
- Greater decision making in the provinces
- Local manufacturing a requirement for EDL products
- Local R&D key driver for access and acceleration
- Chinese data important for drug approvals

Evolution vs revolution: current market exists for foreseeable future

GSK ranked #14 in highly fragmented market



Market share MAT Q2 2010


MAT SIX /0		
1Q2008	2Q2009	2Q2010
28%	30%	27%
32%	30%	30%
49%	26%	32%
38%	25%	20%
19%	23%	26%
47%	53%	53%
25%	15%	26%
54%	27%	26%
20%	22%	23%
32%	24%	15%
31%	12%	14%
31%	38%	30%
15%	27%	28%
69%	37%	34%
31% 31% 15%	12% 38% 27%	14% 30% <mark>28%</mark>

MAT GR%


China - four elements for success




New segments / channels provide opportunity for growth




Sales force expansion continuing



Drivers of growth



Products: Sales and growth 2010 Q3 YTD




N = New Product Launch R = Relaunched Product


Hepatitis B strategy for continued growth

- 1/3 of global Hep B cases are in China
- Invest to maintain competitiveness and share of voice in <u>urban</u> <u>hospitals</u>
- Expand distribution reach and access in <u>rural areas</u>
- Improve patient awareness and diagnosis (Project Rainbow)
- Reinforce presence in Hep B market through development & launch of tenofovir (Viread) – recently in-licensed from Gilead
- Leverage vaccines for prevention

Respiratory – various offerings and pricing strategies improve access and drive volume growth



GSK #1 Vaccine MNC in China



GSK's Position & Strategy

- Diversified & balanced portfolio
- Leadership among MNCs gained in 2009
- #1 Independent vaccine company
- Investing in people and awareness building (healthcare workers and general public)
- Investing in local mfg and partnerships:



- China specific R&D
- Extensive pipeline

CER growth rates; China mainland only (excludes Hong Kong)

Summary

- Sustainable growth achieved
- Investing for further growth
- Leveraging complete GSK portfolio
- Actively exploring portfolio diversification
- Lower exposure to government policy changes
- Capitalizing on market opportunities

